Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Net Margin (2016 - 2025)

Historic Net Margin for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to 2.54%.

  • Immucell's Net Margin rose 91300.0% to 2.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.37%, marking a year-over-year increase of 281300.0%. This contributed to the annual value of 8.14% for FY2024, which is 249100.0% up from last year.
  • As of Q3 2025, Immucell's Net Margin stood at 2.54%, which was up 91300.0% from 7.79% recorded in Q2 2025.
  • Immucell's 5-year Net Margin high stood at 17.94% for Q1 2025, and its period low was 67.17% during Q1 2023.
  • In the last 5 years, Immucell's Net Margin had a median value of 8.39% in 2021 and averaged 11.63%.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -794300bps in 2023, then soared by 611400bps in 2024.
  • Over the past 5 years, Immucell's Net Margin (Quarter) stood at 1.36% in 2021, then crashed by -3232bps to 42.65% in 2022, then soared by 59bps to 17.42% in 2023, then skyrocketed by 138bps to 6.64% in 2024, then crashed by -138bps to 2.54% in 2025.
  • Its last three reported values are 2.54% in Q3 2025, 7.79% for Q2 2025, and 17.94% during Q1 2025.